We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Siemens Healthineers Enters Agreement with HORIBA Medical

By LabMedica International staff writers
Posted on 16 Oct 2017
Siemens Healthineers (Erlangen, Germany) and HORIBA Medical (Montpellier, France) have entered into a long-term agreement to bring new and innovative hematology solutions to the market globally.

Siemens Healthineers offers products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. More...
HORIBA Medical designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medical laboratories, clinics and university hospitals.

With HORIBA Medical as the original equipment manufacturer to complement the Siemens Healthineers portfolio, the companies will provide customers with expanded options to fulfill their hematology and multidisciplinary solution needs. Through this alliance, Siemens Healthineers aims to help laboratories transform care delivery by providing complete multidisciplinary solutions for in vitro diagnostics testing.

"With our commercial strength and global installed base of customers combined with HORIBA Medical's innovative technologies, the relationship will expand the hematology solutions available to laboratories for diagnostics testing worldwide," said Franz Walt, President, Laboratory Diagnostics, Siemens Healthineers.

“Our long-term vision and continuous investments coupled with our outstanding employees have resulted in innovative hematology technology solutions. I am extremely pleased that this long-term vision has resulted in an alliance with Siemens Healthineers” said Mr. Atsushi Horiba, Chairman, President & CEO of HORIBA, Ltd.

“This alliance provides HORIBA Medical the opportunity to address the multidisciplinary requirements along with complimentary innovative technology of Siemens Healthineers. HORIBA Medical will continue offering innovative technology solutions through its Yumizen 2 brand and current distribution channels.” said Dr. Jai Hakhu, Executive Corporate Officer of HORIBA, Ltd. and President of HORIBA Medical.


New
Gold Member
Aspiration System
VACUSAFE
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.